THERAPY DOSSIER · th-a375c65edc03

Human umbilical cord mesenchymal stem cells modified with the angiotensin-converting enzyme 2 gene (ACE2-uMSCs)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25435005 ↗2014Reported benefit

Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury.

MouseChemical/toxinC57BL/6Malen = 100 mice, five groups of 20; five mice per group sacrificed…Injection, route not statedAfter bleomycin pretreatment; interval not stated

Model: Intratracheal bleomycin (40 mg/ml/kg) induced acute lung injury and pulmonary fibrosis

ACE2-uMSC injection significantly alleviated lung injury and reduced Ashcroft fibrosis scores at 14 and 28 days, lowering MDA, GSSG, TNF-alpha, IFN-gamma, TGF-beta, IL-1, IL-2, IL-6, hydroxyproline, collagen type 1 mRNA, MMPs and TIMPs while increasing SOD, GSH, ACE2 and IL-10. The combined constru…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…